Elraglusib (formerly 9-ING-41) possesses potent anti-lymphoma properties which cannot be attributed to GSK3 inhibition

Elraglusib (formerly 9-ING-41) is an ATP-competitive inhibitor of glycogen synthase kinase-3β (GSK3β) undergoing clinical trials for the treatment of various cancers including non-Hodgkin lymphoma (NHL). The drug reduces proliferation of several NHL cell lines and has efficacy in xenograft models of...

Descripción completa

Detalles Bibliográficos
Autores principales: Coats, Josh T., Tauro, Sudhir, Sutherland, Calum
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265916/
https://www.ncbi.nlm.nih.gov/pubmed/37316860
http://dx.doi.org/10.1186/s12964-023-01147-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265916/
https://www.ncbi.nlm.nih.gov/pubmed/37316860
http://dx.doi.org/10.1186/s12964-023-01147-8

Ejemplares similares